Activin and Inhibin

CCG273441 is a covalent inhibitor of G protein-coupled receptor ( GPCR ) kinase 5 ( GRK5 ) with an IC 50 value of 3.8 nM. CCG273441 is highly selective to GRK5 over GRK2 (IC 50 =4.8 μM) by binding Cys474, a GRK5 subfamily-specific residue, as a

CCG273441 is a covalent inhibitor of G protein-coupled receptor ( GPCR ) kinase 5 ( GRK5 ) with an IC 50 value of 3.8 nM. CCG273441 is highly selective to GRK5 over GRK2 (IC 50 =4.8 μM) by binding Cys474, a GRK5 subfamily-specific residue, as a

CCG273441 is a covalent inhibitor of G protein-coupled receptor ( GPCR ) kinase 5 ( GRK5 ) with an IC 50 value of 3.8 nM. CCG273441 is highly selective to GRK5 over GRK2 (IC 50 =4.8 μM) by binding Cys474, a GRK5 subfamily-specific residue, as a

CCI-006 is a selective inhibitor and chemosensitizer of MLL-rearranged leukemia cells, by inhibits mitochondrial respiration resulting in insurmountable mitochondrial depolarization and a pro-apoptotic unfolded protein response (UPR) in a subset of

CCI-006 is a selective inhibitor and chemosensitizer of MLL-rearranged leukemia cells, by inhibits mitochondrial respiration resulting in insurmountable mitochondrial depolarization and a pro-apoptotic unfolded protein response (UPR) in a subset of

CCI-006 is a selective inhibitor and chemosensitizer of MLL-rearranged leukemia cells, by inhibits mitochondrial respiration resulting in insurmountable mitochondrial depolarization and a pro-apoptotic unfolded protein response (UPR) in a subset of

CCI-006 is a selective inhibitor and chemosensitizer of MLL-rearranged leukemia cells, by inhibits mitochondrial respiration resulting in insurmountable mitochondrial depolarization and a pro-apoptotic unfolded protein response (UPR) in a subset of

CCK-B Receptor Antagonist 2, compound 15b, is a potent and orally active Gastrin/CCK-B antagonist with an IC 50 value of 0.43 nM. CCK-B Receptor Antagonist 2 also inhibits gastrin/CCK-A activity with an IC 50 of 1.82 μMIn VivoCCK-B Receptor

CCK-B Receptor Antagonist 2, compound 15b, is a potent and orally active Gastrin/CCK-B antagonist with an IC 50 value of 0.43 nM. CCK-B Receptor Antagonist 2 also inhibits gastrin/CCK-A activity with an IC 50 of 1.82 μMIn VivoCCK-B Receptor

CCK-B Receptor Antagonist 2, compound 15b, is a potent and orally active Gastrin/CCK-B antagonist with an IC 50 value of 0.43 nM. CCK-B Receptor Antagonist 2 also inhibits gastrin/CCK-A activity with an IC 50 of 1.82 μMIn VivoCCK-B Receptor

CCK-B Receptor Antagonist 2, compound 15b, is a potent and orally active Gastrin/CCK-B antagonist with an IC 50 value of 0.43 nM. CCK-B Receptor Antagonist 2 also inhibits gastrin/CCK-A activity with an IC 50 of 1.82 μMIn VivoCCK-B Receptor

CCK-B Receptor Antagonist 2, compound 15b, is a potent and orally active Gastrin/CCK-B antagonist with an IC 50 value of 0.43 nM. CCK-B Receptor Antagonist 2 also inhibits gastrin/CCK-A activity with an IC 50 of 1.82 μMIn VivoCCK-B Receptor